DropGenie raises Seed+ to commercialise its gene-editing automation platform
What's the deal? DropGenieDealroom has a profile for this one. Try Dealroom →, a biotech with offices in Montreal and Boston, has closed a Seed+ round to commercialise its first product.
The raise was led by Skeleton Key, with new backers Merck Global Health Innovation FundDealroom has a profile for this one. Try Dealroom → and CQDMDealroom has a profile for this one. Try Dealroom → joining existing investors Real Ventures and Anges Québec.
The company builds high-throughput, miniaturised gene editing workflows that cut the cells and reagents needed per experiment.
That lowers costs and speeds up turnaround, letting researchers edit primary patient cells directly for more biologically relevant insights.
Why now? The round follows DropGenie's Early Access Program, with major pharma, biotech, and research customers already using the technology.
The new cash will scale manufacturing, build commercial operations, and drive customer adoption through a full product launch.
What could go wrong? DropGenie still has to prove its platform works at commercial scale, not just in early trials.
It also faces the challenge of convincing more pharma and research customers to fold its tools into established workflows.
The signal: The presence of Merck Global Health Innovation Fund, a corporate strategic investor, alongside Quebec's CQDM signals that the early-stage startup's miniaturised approach has caught the eye of pharma incumbents looking to embed gene editing data into their pipelines. For a company still classed as early stage, that mix of corporate and regional backing points to a bet that standardised primary cell data could become critical infrastructure for AI-driven drug discovery.
Read more: streetinsider.com
